Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
9,8 USD | -0,51% | +12,26% | +92,91% |
Attività
Numero di dipendenti: 49
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Radiotherapies
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -92,14% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -92,14% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Sandesh Seth
CEO | Chief Executive Officer | 60 | 01/03/12 |
Steve O'Loughlin
DFI | Director of Finance/CFO | 39 | 13/10/15 |
Monideepa Roy
CTO | Chief Tech/Sci/R&D Officer | - | 27/09/21 |
Mary Mei Chen
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/20 |
Avinash Desai
CTO | Chief Tech/Sci/R&D Officer | - | 19/11/20 |
Stephen Dressel
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - | |
Jenny Hsieh
PRN | Corporate Officer/Principal | - | - |
Paul Diamond
LAW | General Counsel | - | 01/07/21 |
Gary Siegel
AUD | Comptroller/Controller/Auditor | 66 | 01/01/17 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 66 | 08/11/13 | |
C. Nicholson
BRD | Director/Board Member | 68 | 01/01/08 |
Ajit Shetty
BRD | Director/Board Member | 77 | 28/03/17 |
Sandesh Seth
CEO | Chief Executive Officer | 60 | 01/03/12 |
Jeffrey Chell
BRD | Director/Board Member | 70 | 01/04/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 29 783 451 | 29 147 811 ( 97,87 %) | 0 | 97,87 % |
Coordinate società
Actinium Pharmaceuticals, Inc.
100 Park Avenue 23rd floor
10017, New York
+646 677 3870
http://www.actiniumpharma.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+92,91% | 292 Mln | |
+9,42% | 115 Mrd | |
+11,84% | 106 Mrd | |
-1,05% | 21,96 Mrd | |
-14,15% | 21,87 Mrd | |
-5,29% | 19,21 Mrd | |
-4,16% | 18,08 Mrd | |
-38,29% | 17,71 Mrd | |
+7,99% | 14,32 Mrd | |
+36,24% | 12,42 Mrd |
- Borsa valori
- Azioni
- Azione ATNM
- Società Actinium Pharmaceuticals, Inc.